Barclays PLC Vectiv Bio Holding Ag Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023
BUY
$7.79 - $8.98 $12,464 - $14,368
1,600 Added 20.49%
9,407 $82,000
Q3 2022

Nov 03, 2022
BUY
$4.7 - $6.07 $36,692 - $47,388
7,807 New
7,807 $47,000

Others Institutions Holding VECT

# of Institutions
1
Shares Held
510K
Call Options Held
0
Put Options Held
0
View Full List

About VectivBio Holding AG

VECT Quotes by TradingView
  • Ticker VECT
  • Exchange NASDAQ
  • Description
  • VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with sho...
More about VECT
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email